

VRL/SEC/EXCHANGE

31.01.2022

National Stock Exchange of India Ltd. 5 th Floor, Exchange Plaza Bandra (E), Mumbai- 400 051	BSE Limited 25 th Floor, Phiroze Jeejeebhoy Towers Dalal Street Mumbai Script Code: 526953
-------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------

Sub: Submission of Unaudited Financial results for the quarter and nine months ended on 31.12.2021

Dear Sir/Madam,

Please find enclosed herewith Unaudited Financial Results for the quarter and nine months ended on 31st December 2021 along with Limited Review report which were taken on record by the Board of Directors at its meeting held on 31st January 2022.

Kindly acknowledge the receipt.

Thanking you.

Yours faithfully,
for **VENUS REMEDIES LIMITED**


Neha
(Company Secretary)

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I, Panchkula (Hry.) 134113, India

Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India

Website : www.venusremedies.com
www.vmrindia.com

email : info@venusremedies.com
CIN No. : L24232CH1989PLC009705

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566

Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272

Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany

Independent Auditor's Limited Review Report on Quarter and Nine Months ended Unaudited Consolidated financial results of VENUS REMEDIES LIMITED pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended

To
The Board of Directors
VENUS REMEDIES LIMITED

1. We have reviewed the accompanying consolidated financial results of **VENUS REMEDIES LIMITED (the "Holding company")** and its subsidiary (**collectively referred to as 'the Group'**), for the quarter and nine months ended 31st December 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

This Statement, which is the responsibility of the Holding company's Management and approved by the Holding company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
3. The Statement includes the results of the following Subsidiary:
 - i. Venus Pharma Gmbh
4. Based on our review conducted and procedures performed as stated in paragraph 2 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Head Office:
4696 Brij Bhawan
21A Ansari Road
Darya Ganj,
New Delhi- 110002, INDIA
Tel : +91-11-2328-8101


Corporate Office:
GLOBAL BUSINESS SQUARE
Building No. 32, Sector 44,
Institutional Area Gurgaon,
122003, India
Tel : +91-124-4786-200

Nehru Place:
503, Chiranjiv Tower,
43, Nehru Place
New Delhi 110019, India
+91-11-2622-3712,
2622-6933

Mumbai:
GR - 108,,
WeWork Vijay Diamond,
No. A3&B2, B Cross Road
Marol Industrial Area,
MIDC, Andheri (East)
Mumbai - 400093

Karol Bagh:
17A/55, Triveni Plaza,
Gurudwara Road,
Karol Bagh,
New Delhi- 110005
Tel : +91-11-4504-4453

Chandigarh, Delhi
SCO-205, 1st Floor,
NAC, Manimajra,
Chandigarh-160101, India
Tel : +91-172-5099-289,
5077-790



5. Emphasis of matter

We draw attention to note no.5 of the consolidated financial results with respect to review of liability related to FCCB bonds amounting to US \$ 4.59 Million in the absence of any explicit agreement and based on reassessment of liability in terms of the provisions of The Limitation Act,1963. Accordingly the carrying value of such FCCB liability has not been reinstated at current exchange rate. No provision for interest payable has been made since 1st February 2015, as the FCCB Bonds liability becoming time barred, as per a legal opinion obtained by the Holding Company.

Our conclusion on the statement is not modified in respect of the above matter.

6. Other Matter

We did not review the interim financial results and other financial information of a subsidiary included in the Statement, whose interim financial results and other financial information reflect total revenues of Rs. 297.71 Million and Rs 740.27 Million, total net profit/ (loss) after tax of Rs. (22.03) Million and Rs. (60.75) Million and total comprehensive (loss) of Rs. (22.03) Million and Rs (60.75) Million for the quarter and nine months ended 31st December 2021 respectively, as considered in the consolidated unaudited financial results. These interim financial results and other financial information have been reviewed by other auditor whose report have been furnished to us by the management and our observations on the Statement, in so far as it relates to the amounts and disclosures included in respect of such subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 2 above.

Our conclusion on the Statement is not modified in respect of the above matter.

For Vinod Kumar & Associates

Chartered Accountants

FRN-002304N



Mukesh Dadhich

Partner

M.No. 511741

UDIN: 22511741AAAACQ1619

Date: 31st January, 2022





STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED ON 31ST DECEMBER, 2021

(Rs in Million)

S. No.	PARTICULARS	QUARTER ENDED ON			NINE MONTH ENDED ON		YEAR ENDED ON
		31/12/2021	30/09/2021	31/12/2020	31/12/2021	31/12/2020	31/03/2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue						
	(a) Revenue from Operations	1243.44	2025.60	1219.38	4567.15	4367.52	5481.23
	(b) Other Income	12.16	28.90	18.27	60.60	161.38	196.30
	Total Income	1255.60	2054.50	1237.65	4,627.75	4,528.90	5,677.53
2	Expenses						
	(a) Cost of Material Consumed	644.79	1098.42	674.70	2,892.11	2683.57	3479.40
	(b) Changes in Inventories of finished goods, work-in-progress, Stock in Trade	102.94	262.57	13.82	10.22	(26.18)	(71.47)
	(c) Employee benefits expense	132.21	124.99	120.05	384.83	354.14	460.19
	(d) Finance Cost	3.14	0.27	18.12	4.81	120.58	130.19
	(e) Depreciation & amortization expense	86.41	87.08	86.97	259.71	258.95	352.76
	(f) Selling, Manufacturing and Administrative expenses	192.24	191.60	193.60	564.02	748.12	917.77
	(g) Research & Development expenses	46.91	74.98	36.39	150.27	115.06	157.58
	Total Expense	1,208.62	1,839.91	1,143.65	4,265.97	4,254.24	5,426.42
3	Profit before exceptional items and taxes (1-2)	46.98	214.59	94.00	361.77	274.66	251.11
	Operating profit	126.04	275.78	180.82	572.00	492.81	537.77
4	Exceptional items	-	-	44.64	-	28.89	234.42
5	Profit before tax (3 +/- 4)	46.98	214.59	138.64	361.77	303.55	485.53
6	Income Tax Expense /Deferred Tax(Benefits)	(9.48)	(16.89)	22.09	(43.14)	36.99	(132.12)
7	Net Profit /(Loss) for the period (5- 6)	56.46	231.48	116.55	404.91	266.56	617.65
8	Other Comprehensive Income (Net of taxes)						
A	(I) Items that will not be classified to profit & loss	(0.24)	(0.24)	(0.38)	(0.71)	(1.64)	(0.95)
B	(II) Items that will be classified to profit & loss	-	-	-	-	-	-
	Total other comprehensive Income Net of Income Tax	(0.24)	(0.24)	(0.38)	(0.71)	(1.64)	(0.95)
9	Total comprehensive Income for the period (7+/-8)	56.22	231.25	116.17	404.20	264.92	616.70
10	Paid up equity share capital	133.67	133.67	123.42	133.67	123.42	123.42
	(Face Value of Equity Shares)	10	10	10	10	10	10
11	Other Equity	-	-	-	-	-	3,879.42
12	Earning per share (of Rs. 10/- each) (Not annulized)						
	(a) Basic	4.22	17.32	9.44	30.68	21.60	50.04
	(b) Diluted	4.22	17.32	9.44	30.68	21.60	50.04

For VENUS REMEDIES LIMITED

CHAIRMAN & MANAGING DIRECTOR



Notes to the consolidated financial results:-

1. The above consolidated Financial Results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on January 31, 2022. The statutory auditors of the company have carried out limited review of the above Consolidated Financial Results for the Quarter and Nine Months ended December 31, 2021 pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.
2. The consolidated financial results are prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
3. During the period under review, the Holding Company had made allotment of 10,25,000 fully paid-up equity shares pursuant to conversion of 10,25,000 "Fully Convertible Warrants" on 31st May, 2021.
4. The group has taken into account external and internal information for assessing possible impact of COVID-19 on various elements of its consolidated financial results, including recoverability of its assets.
5. The FCCB bonds of US \$ 4.59 Million became due for maturity on 1st February, 2015. The bondholder(s) or their custodian bank did not submit the bonds for conversion or redemption. FCCB Bonds liability becoming time barred in terms of the provisions of The Limitation Act, 1963, as per a legal opinion obtained by the Holding Company. The carrying value of such FCCB liability has not been reinstated at current exchange rate. No provision for interest payable has been made since 1st February 2015. The board of directors in their meeting held on 31st May, 2021 have decided that further course of action be sought from the Reserve Bank of India.





6. The Code of Social Security 2020 ('Code') relating to employee benefits during employment and post-employment received Presidential assent in September 2020.

The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/interpretation have not yet been issued. The group will assess the impact of the Code when it comes into effect and will record any related impact in the period in which the Code becomes effective.

7. Previous year / period figures have been regrouped/ reclassified wherever necessary.
8. The group has only one reportable segment namely "Pharmaceuticals"

For and on behalf of Board of Directors

For VENUS REMEDIES LIMITED

A handwritten signature in black ink, appearing to read "Pawan Chaudhary".

Pawan Chaudhary

(Chairman and Managing Director)

DIN: 00435503

Date: 31-01-2022



Independent Auditor's Limited Review Report On Quarter and Nine Months Ended Unaudited Standalone Financial Results of VENUS REMEDIES LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

The Board of Directors

VENUS REMEDIES LIMITED

1. We have reviewed accompanying statement of unaudited standalone financial results of **VENUS REMEDIES LIMITED** ("the Company"), for the quarter and nine months ended 31st December, 2021 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement which is responsibility of company's Management has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to report a conclusion on these statements based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.



Head Office:

4696 Brij Bhawan
21A Ansari Road
Darya Ganj,
New Delhi-110002, INDIA
Tel : +91-11-2328-8101

Corporate Office:

GLOBAL BUSINESS SQUARE
Building No. 32, Sector 44,
Institutional Area Gurgaon,
122003, India
Tel : +91-124-4786-200

Nehru Place:

503, Chiranjiv Tower,
43, Nehru Place
New Delhi 110019, India
+91-11-2622-3712,
2622-6933

Mumbai:

GR - 108.,
WeWork Vijay Diamond,
No. A3&B2, B Cross Road
Marol Industrial Area,
MIDC, Andheri (East)
Mumbai - 400093

Karol Bagh:

17A/55, Triveni Plaza,
Gurudwara Road,
Karol Bagh,
New Delhi- 110005
Tel : +91-11-4504-4453

Chandigarh:

SCO-705, 1st Floor,
NAC Manimajra
Chandigarh-160101, India
Tel : +91-172-507-7789,
5077-790

4. Emphasis of matter:

We draw attention to note no.5 of the standalone financial results with respect to review of liability related to FCCB bonds amounting to US \$ 4.59 Million in the absence of any explicit agreement and based on reassessment of liability in terms of the provisions of The Limitation Act,1963. Accordingly, the carrying value of such FCCB liability has not been reinstated at current exchange rate. No provision for interest payable has been made since 1st February 2015, as the FCCB Bonds liability becoming time barred, as per a legal opinion obtained by the Company.

Our conclusion is not modified in respect of above matter.

For Vinod Kumar & Associates

Chartered Accountants

FRN-002304N



Mukesh Dadhich


Partner

M.No. 511741

UDIN: 22511741AAAACP4094

Date: 31st January, 2022





STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31st DECEMBER, 2021

(Rs. in Million)

S. No.	PARTICULARS	QUARTER ENDED ON			Nine month ended on		YEAR ENDED ON
		31/12/2021	30/09/2021	31/12/2020	31/12/2021	31/12/2020	31/03/2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue						
	(a) Revenue from Operations	1174.42	1926.43	1140.65	4469.33	4121.83	5146.23
	(b) Other Income	10.72	29.63	11.53	59.53	143.99	177.62
	Total Income	1,185.14	1,956.06	1,152.18	4,528.86	4,265.82	5,323.85
2	Expenses						
	(a) Cost of Material Consumed	690.36	1101.41	674.08	2860.09	2645.38	3440.44
	(b) Changes in Inventories of finished goods, work-in-progress, Stock in Trade	11.71	195.95	41.37	33.67	46.15	(73.56)
	(c) Employee benefits expense	111.46	103.24	91.65	320.43	275.65	358.88
	(d) Finance Cost	-	-	17.32	-	118.59	127.26
	(e) Depreciation & amortization expense	84.00	84.58	84.24	252.25	251.03	342.80
	(f) Selling, Manufacturing and Administrative expenses	172.82	184.27	166.79	503.51	649.62	793.20
	(g) Research & Development expenses	45.79	62.22	36.38	136.39	115.06	158.65
	Total Expense	1,116.14	1,731.67	1,111.83	4,106.34	4,101.48	5,147.67
3	Profit before exceptional items and taxes (1-2)	69.00	224.39	40.35	422.52	164.34	176.18
	Operating Profit	143.89	282.00	130.38	621.32	389.97	468.63
4	Exceptional items	-	-	44.66	-	28.89	234.42
5	Profit before tax (3 +/- 4)	69.00	224.39	85.01	422.52	193.23	410.60
6	Income Tax Expense /Deferred Tax(Benefits)	(9.48)	(16.89)	22.09	(43.14)	36.99	(132.12)
7	Net Profit /(Loss) for the period (5- 6)	78.48	241.28	62.92	465.66	156.24	542.72
8	Other Comprehensive Income (Net of taxes)						
A	(I) Items that will not be classified to profit & loss	(0.24)	(0.24)	(0.38)	(0.71)	(1.64)	(0.95)
B	(II) Items that will be classified to profit & loss	-	-	-	-	-	-
	Total other comprehensive Income Net of Income Tax	(0.24)	(0.24)	(0.38)	(0.71)	(1.64)	(0.95)
9	Total comprehensive Income for the period (7+/-8)	78.24	241.04	62.54	464.95	154.60	541.77
10	Paid up equity share capital (Face Value of Equity Shares)	133.67 10	133.67 10	123.42 10	133.67 10	123.42 10	123.42 10
11	Other Equity	-	-	-	-	-	3,878.41
12	Earning per share (of Rs. 10/- each) (Not annulized)						
	(a) Basic	5.87	18.05	5.10	35.29	12.66	43.97
	(b) Diluted	5.87	18.05	5.10	35.29	12.66	43.97


For VENUS REMEDIES LIMITED

 CHAIRMAN & MANAGING DIRECTOR



Notes to the standalone financial results:-


1. The above Standalone Financial Results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on January 31, 2022. The statutory auditors of the company have carried out limited review of the above standalone Financial Results for the Quarter and Nine Months ended December 31, 2021, pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.
2. The standalone financial results are prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
3. During the period under review, the company had made allotment of 10,25,000 fully paid-up equity shares pursuant to conversion of 10,25,000 "Fully Convertible Warrants" on 31st May, 2021.
4. The Company has taken into account external and internal information for assessing possible impact of COVID-19 on various elements of its standalone financial results, including recoverability of its assets.
5. The FCCB bonds of US \$ 4.59 Million became due for maturity on 1st February 2015. The bondholder(s) or their custodian bank did not submit the bonds for conversion or redemption. FCCB Bonds liability becoming time barred in terms of the provisions of The Limitation Act, 1963, as per a legal opinion obtained by the parent Company. The carrying value of such FCCB liability has not been reinstated at current exchange rate. No provision for interest payable has been made since 1st February 2015. The board of directors in their meeting held on 31st May, 2021 have decided that further course of action be sought from the Reserve Bank of India.



6. The Code of Social Security 2020 ('Code') relating to employee benefits during employment and post-employment received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/interpretation have not yet been issued. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period in which the Code becomes effective.
7. Previous year / period figures have been regrouped/ reclassified wherever necessary.
8. The Company has only one reportable segment namely "Pharmaceuticals"



For and on behalf of Board of Directors
For VENUS REMEDIES LIMITED



Pawan Chaudhary

(Chairman and Managing Director)

DIN: 00435503

Date: 31-01-2022